Glycogen synthase kinase-3 (GSK-3) mediates epidermal growth factor, insulin and Wnt signals to various downstream events such as glycogen metabolism, gene expression, proliferation and differentiation. We have isolated here a GSK-3β-interacting protein from a rat brain cDNA library using a yeast twohybrid method. This protein consists of 832 amino acids and possesses Regulators of G protein Signaling (RGS) and dishevelled (Dsh) homologous domains in its N-and C-terminal regions, respectively. The predicted amino acid sequence of this GSK-3β-interacting protein shows 94% identity with mouse Axin, which recently has been identified as a negative regulator of the Wnt signaling pathway; therefore, we termed this protein rAxin (rat Axin). rAxin interacted directly with, and was phosphorylated by, GSK-3β. rAxin also interacted directly with the armadillo repeats of β-catenin. The binding site of rAxin for GSK-3β was distinct from the β-catenin-binding site, and these three proteins formed a ternary complex. Furthermore, rAxin promoted GSK-3β-dependent phosphorylation of β-catenin. These results suggest that rAxin negatively regulates the Wnt signaling pathway by interacting with GSK-3β and β-catenin and mediating the signal from GSK-3β to β-catenin.
Introduction
Glycogen synthase kinase-3 (GSK-3) was originally characterized as a serine/threonine kinase that phosphorylates and inactivates glycogen synthase, and subsequently was demonstrated to be identical to protein kinase F A that activates ATP-Mg-dependent type-1 protein phosphatase (Plyte et al., 1992) . GSK-3 is now implicated in the regulation of several physiological responses in mammalian cells by phosphorylating many substrates including neuronal cell adhesion molecule, neurofilament, synapsin I, tau, transcription factors and adenomatous polyposis coli (APC) gene product (Mandelkow et al., 1992; Plyte et al., 1992; Yang et al., 1992; Rubinfeld et al., 1996) . The cDNAs of GSK-3α and GSK-3β in mammals have been isolated and they encode the protein kinases with M r s of 51 and 47 kDa, respectively (Woodgett, 1990 ).
Mammalian GSK-3β is structurally and functionally homologous to the Drosophila zeste-white3/shaggy gene product (Ruel et al., 1993) . The shaggy gene product has been found to be required at several developmental stages during fruit fly embryogenesis for correct embryogenic segmentation (Simpson et al., 1988; Perrimon and Smouse, 1989) . In Saccharomyces cerevisiae, the MCK1 and MDS1 genes encode serine/threonine kinases which are homologous to mammalian GSK-3 and to the Drosophila shaggy gene product. The MCK1 and MDS1 gene products play a role in the chromosomal segregation processes (Puziss et al., 1994) . In Schizosaccharomyces pombe, the skp1 ϩ gene product is a homolog of GSK-3 and regulates cytokinesis (Plyte et al., 1996) . Xenopus GSK-3 has been shown to regulate ventral differentiation during early Xenopus development (He et al., 1995) . Furthermore, the Dictyostelium homolog of GSK-3 (GSKA) has been found to be important for cellular differentiation (Harwood et al., 1995) . Thus, GSK-3 is highly conserved throughout evolution and plays a fundamental role in cellular responses.
Genetic evidence reveals that Drosophila wingless signals through an intracellular cascade that includes dishevelled (Dsh), shaggy and armadillo, a β-catenin homolog Nusse, 1997) . In the absence of a wingless signal, shaggy antagonizes downstream elements of the wingless pathway via changes in the level of armadillo and, in response to wingless signaling, there is a decrease in the phosphorylation of armadillo and an increase in its stability. In Xenopus, interference with GSK-3 induces an ectopic dorsal axis which is identical to that resulting from overexpression of Wnt and β-catenin (He et al., 1995) . In mammals, it has been shown also that GSK-3 is inactivated by Wnt, although the mechanism is not clear (Cook et al., 1996) , and that β-catenin accumulates in the cytoplasm following the Wnt signals and translocates to the nucleus (Polakis, 1997) . This translocation involves the association of β-catenin with the transcriptional enhancers of lymphocyte enhancer binding factor/T cell factor (LEF/TCF) family (Behrens et al., 1996; Molenaar et al., 1996) . A dominantnegative form of Xenopus TCF-3 inhibits axis formation (Molenaar et al., 1996) . Furthermore, it has been shown that GSK-3β phosphorylates APC and that the phosphorylation enhances the binding of APC to β-catenin . It is well known that APC is required for the degradation of β-catenin, although the role of APC is not well understood (Polakis, 1997) . Thus, the Wnt signaling pathway through GSK-3β regulates the determination of cell fate. In specifying cell fate, GSK-3β may interact with several cellular targets. Apart from the demonstration of GSK-3β binding to APC-β-catenin complex , GSK-3β may have other binding partners as well.
β-Catenin has a consensus sequence phosphorylation site for GSK-3β, and GSK-3β acts to cause the degradation of β-catenin . Elimination of the possible phosphorylation site increases the stability of β-catenin Yost et al., 1996) . It has been shown recently that the ubiquitination-proteasome pathway is involved in the degradation of β-catenin and that mutations in the GSK-3β consensus phosphorylation site of β-catenin prevent ubiquitination (Aberle et al., 1997) . Thus, it appears that GSK-3β phosphorylates β-catenin and that the phosphorylation of β-catenin is essential for its degradation. Indeed, it has been reported that in Xenopus, GSK-3β phosphorylates β-catenin in vitro (Yost et al., 1996) . However, it has been shown that mammalian GSK-3β does not significantly phosphorylate β-catenin in vitro . These results suggest that the factor(s) involved in the phosphorylation of β-catenin may be lost.
To obtain further insights into the action of GSK-3β on the degradation of β-catenin, we have tried to find a GSK-3β-interacting protein using a yeast two-hybrid method. From a rat brain cDNA library, we have isolated a protein which interacts with GSK-3β, and we found that this protein shared 94% identity with mouse Axin (Zeng et al., 1997) , indicating that it is rat Axin (rAxin). Axin has been found to regulate negatively a critical step in the formation of the embryonic axis and exert its effects at a very early stage by specifically inhibiting the Wnt signaling pathway (Zeng et al., 1997) . We show here that rAxin is phosphorylated by GSK-3β and that it directly interacts with both GSK-3β and β-catenin. Furthermore, we demonstrate that rAxin promotes GSK-3β-dependent phosphorylation of β-catenin. These results suggest that Axin negatively regulates the Wnt signaling pathway by interacting with GSK-3β and β-catenin and mediating the signal from GSK-3β to β-catenin.
Results

Isolation of GSK-3β-interacting protein
To identify proteins that physically interact with GSK-3β, we conducted a rat brain cDNA library screening by the yeast two-hybrid method. From 3.7ϫ10 6 initial transformants, four clones were found to confer both the His ϩ and LacZ ϩ phenotypes on L40 containing pBTM116HA/ GSK-3β. Among these, a 3.2 kb cDNA insert was found to encode a sequence containing a long open reading frame (ORF) and the consensus sequence for a stop codon. Further, the protein encoded by this cDNA shared high homology with Regulators of G protein Signaling (RGS) and Dsh. Therefore, we tried to characterize this clone and did not analyze the other clones further here.
A full-length cDNA of this GSK-3β-interacting protein was isolated from a rat brain cDNA library. This clone spanned a distance of 3.5 kb and contained an uninterrupted ORF of 2496 bp, encoding a predicted protein of 832 amino acids with a calculated M r of 92 855 Da ( Figure 1A ). The first ATG was preceded by stop codons in all three reading frames, and the 5Ј-non-coding region had a high percentage of GC base pairs (81%). The neighboring sequence of the second ATG was more consistent than that of the first with the translation initiation start proposed by Kozak (1987) , but we could not determine which is the first Met. When we isolated this cDNA, besides dbEST sequences (DDBJ/EMBL/GenBank Accession nos: AA198606, AA028403, AA238939, W97777, AA259709 and AA170717), no protein closely related to this GSK-3β-interacting protein was identified. However, during preparation of this manuscript, this protein was found to share 94% amino acid identity with mouse Axin (Zeng et al., 1997) , so we designated this GSK-3β-interacting protein rAxin (rat Axin). Although it appears that the ORF of mouse Axin extends upstream of rAxin, it has been suggested that the first or second Met of mouse Axin, which is in the same position as that of rAxin, could serve as an initiation codon (Zeng et al., 1997) . There are alternative splicing products, termed form 1 and 2, in mouse Axin. A 36 amino acid segment is inserted in form 2. The rAxin that we isolated is form 1, since 36 amino acids which correspond to mouse Axin (860-895) are lacking. The N-terminal region of rAxin, residues 89-216, shared 31% amino acid identity with residues 58- 178 of RGS4, which has been identified as a GTPaseactivating protein (GAP) for heterotrimeric GTP-binding protein (G protein) (Druey et al., 1996) (Figure 1B and C). The C-terminal region, residues 757-820, shared 37% amino acid identity with residues 8-73 of the mouse Dsh homolog, DVL-1 (Sussman et al., 1994) (Figure 1B and C). A single band of 4.8 kb rAxin mRNA was detected ubiquitously in those rat tissues which we examined ( Figure 1D ).
Interaction of rAxin with GSK-3β
To examine whether rAxin interacts with GSK-3β in intact cells, we co-expressed rAxin with GSK-3β in COS cells (Figure 2A ). rAxin and GSK-3β were tagged with Myc and hemagglutinin 1 (HA) epitopes, respectively, at their N-termini. HA-GSK-3β and endogenous GSK-3β were detected by the anti-GSK-3β antibody. When the lysates co-expressing Myc-rAxin with HA-GSK-3β were immunoprecipitated with the anti-Myc antibody, HA-GSK-3β was detected in the Myc-rAxin immune complex ( Figure 2B, lanes 1-3) . Similarly, when the same lysates were immunoprecipitated with the anti-HA antibody, MycrAxin was detected in the HA-GSK-3β immune complex ( Figure 2B , lanes 4-6). Neither Myc-rAxin nor HA-GSK-3β was immunoprecipitated from the lysates expressing both proteins with non-immune immunoglobulin (data not shown). To show that Myc-rAxin interacts with endogenous GSK-3α and GSK-3β, the lysates expressing Myc-rAxin alone were immunoprecipitated with the antiMyc antibody. Endogenous GSK-3α and GSK-3β were co-precipitated with Myc-rAxin ( Figure 2C ). These results suggest that rAxin forms a complex with GSK-3α and GSK-3β in intact cells. HA-GSK-3β K85M and HA-GSK-3β Y216F , in which ATP binding and tyrosine phosphorylation sites respectively are mutated, were expressed in COS cells. Neither HA-GSK-3β K85M nor HA-GSK-3β Y216F showed kinase activities for GSK peptide 1 (data not shown). Co-transfection of Myc-rAxin with these HA-GSK-3β mutants did not alter the level of expression of transfected Myc-rAxin as assessed by immunoblot analysis (data not shown). When these lysates were immunoprecipitated with the anti-HA antibody, Myc-rAxin was not co-precipitated with HA-GSK-3β K85M or HA-GSK-3β Y216F ( Figure 2D ). These results suggest that the kinase activity of GSK-3β may be necessary for its complex formation with rAxin.
To determine which region of rAxin interacts with GSK-3β, various deletion mutants of Myc-rAxin were expressed in COS cells (Figure 3A and B, upper panel) . When the lysates expressing Myc-rAxin mutants were immunoprecipitated with the anti-Myc antibody, endogenous GSK-3β was co-precipitated with Myc-rAxin (full-length), Myc-rAxin-(298-832), Myc-rAxin-(1-713), Myc-rAxin-(298-713) and Myc-rAxin-(298-506), but not with Myc-rAxin-(508-832), Myc-rAxin-(713-832) or Myc-rAxin-(1-229) ( Figure 3B , lower panel). These results indicate that the region containing residues 298-506 of rAxin is sufficient and necessary for its complex formation with GSK-3β.
Phosphorylation of rAxin by GSK-3β
To determine whether rAxin is a substrate for GSK-3β, Myc-rAxin immunoprecipitated from the COS cell lysates was incubated with or without glutathione S-transferase (GST) fused to GSK-3β (GST-GSK-3β). rAxin was phosphorylated without GST-GSK-3β, and this phosphorylation was enhanced by GST-GSK-3β ( Figure 4A ). GST-GSK-3β phosphorylated Myc-rAxin in a time-and dose-dependent manner (Figure 4B and C) . Approximately 3-4 mol of phosphate was maximally incorporated into 1 mol of Myc-rAxin. In Figure 2C , we show that endogenous GSK-3β is co-precipitated with Myc-rAxin. Therefore, the phosphorylation of Myc-rAxin without GST-GSK-3β might be due to the associated endogenous GSK-3β. However, we cannot rule out the possibility that GSK-3β phosphorylates and activates other protein kinases which interact with and phosphorylate Myc-rAxin. Alternatively, other protein kinases associated with Myc-rAxin might phosphorylate it independently of GSK-3β.
To determine which regions of rAxin were phosphorylated by GSK-3β, various deletion mutants of Myc-rAxin described in Figure 3A were immunoprecipitated from the COS cell lysates. Myc-rAxin (full-length), Myc-rAxin-(298-832), Myc-rAxin-(1-713), and were phosphorylated by GST-GSK-3β ( Figure 4D , lanes 1, 2 and 6-8); however, MycrAxin-(508-832), Myc-rAxin-(713-832) and Myc-rAxin-(1-229) were not (lanes 3-5). These results indicate that Myc-rAxin-(298-506) contains at least one phosphoryl-ation site for GSK-3β. Taken together with the observations in Figure 3 , the physical interaction of rAxin with GSK-3β may be required for the phosphorylation of rAxin.
To examine whether endogenous Axin interacts with GSK-3β in intact cells, the COS cell lysates were immunoprecipitated with the anti-GSK-3β antibody, and the immunoprecipitates were incubated in the kinase reaction mixture. The protein with an M r of 105 kDa, which is similar to the M r of Myc-rAxin, was phosphorylated, but this phosphorylated protein was not observed in the immunoprecipitates with non-immune immunoglobulin ( Figure 4E ). These results suggest that endogenous Axin forms a complex with and is phosphorylated by GSK-3β.
Kinetics of the phosphorylation of rAxin-(298-506) by GSK-3β and the interaction of rAxin-(298-506) with GSK-3β
To rule out the involvement of endogenous GSK-3β in the phosphorylation of and interaction with rAxin, we purified rAxin-(298-506) from Escherichia coli as a maltose-binding protein (MBP) fusion protein. GST-GSK-3β phosphorylated MBP-rAxin-(298-506) in a timedependent manner ( Figures 4F and 5A ). The K m value for the phosphorylation of MBP-rAxin-(298-506) by GST-GSK-3β was calculated to be 93 nM. The sequence S/ TXXXS/T is known to be a consensus sequence for a GSK-3β phosphorylation site (Plyte et al., 1992) . In residues 298-506 of rAxin, there are three possible phosphorylation sites: SANDSEQQS 330 , SDADTLSLT 341 and SLTDS 343 . All serine and threonine residues of these possible phosphorylation sites were substituted by alanine, and the phosphorylation of these mutants by GST-GSK-3β was examined. The phosphorylation levels of MBPrAxin-(298-506, 322/326/330A), MBP-rAxin-(298-506, 333/337/341A) and MBP-rAxin-(298-506, 339/343A) by GST-GSK-3β were reduced to 55-60% of wild-type ( Figure 4F ). These results indicate that rAxin is directly phosphorylated by GSK-3β and that it has multiple phosphorylation sites for GSK-3β. MBP-rAxin-(298-506) bound to GST-GSK-3β in a dose-dependent manner, and the K d value of the binding was~65 nM ( Figure 5B ). These results indicate that rAxin directly interacts with GSK-3β. Neither GST-GSK-3β K85M nor GST-GSK-3β Y216F exhibited kinase activities for GSK peptide 1 (data not shown). Consistent with the results in Figure 2D , MBP-rAxin-(298-506) did not bind to these GSK-3β mutants ( Figure 5B ). Since ATP was not used in this experiment, it is suggested that the interaction of rAxin with GSK-3β does not require the phosphorylation of rAxin but that the interaction may require the structure of GSK-3β which is catalytically active.
Interaction of rAxin with β-catenin
It has been demonstrated that Axin negatively regulates the Wnt signaling pathway either at the level of GSK-3 to GSK-3β. GST-GSK-3β (d), GST-GSK-3β K85M (s) and GST-GSK-3β Y216F (n) (2.2 pmol each) immobilized to glutathione-Sepharose 4B were incubated with the indicated concentrations of MBP-rAxin-(298-506) for 2 h. After GST-GSK-3β and its mutants were precipitated by centrifugation, the precipitates were probed with the anti-MBP antibody and the amounts of interacted MBP-rAxin-(298-506) were quantified by densitometric tracing. The results shown are representative of three independent experiments. or further downstream of GSK-3, and that it acts upstream of β-catenin (Zeng et al., 1997) . Therefore, we next examined the relationship between rAxin and β-catenin. β-Catenin was expressed in COS cells ( Figure 6A ). When the lysates expressing Myc-rAxin were immunoprecipitated with the anti-Myc antibody, endogenous β-catenin was co-precipitated with Myc-rAxin ( Figure 6A ). Neither Myc-rAxin nor β-catenin were immunoprecipitated from the lysates expressing Myc-rAxin with non-immune immunoglobulin (data not shown). Myc-rAxin was coprecipitated with GST-β-catenin-(1-423) but not with GST-β-catenin-(423-781) from the COS cell lysates ( Figure 6B ). These results suggest that rAxin forms a complex with the N-terminal region of β-catenin in intact cells. To determine which region of rAxin binds to β-catenin, various deletion mutants of Myc-rAxin described in Figure 3A were expressed in COS cells, and the lysates were immunoprecipitated with the anti-Myc antibody. Endogenous β-catenin was co-precipitated with Myc-rAxin (full-length), Myc-rAxin-(298-832), MycrAxin-(1-713), Myc-rAxin-(298-713) and Myc-rAxin-(298-506), but not with Myc-rAxin-(508-832), MycrAxin-(713-832) or Myc-rAxin-(1-229) ( Figure 6C ). These results indicate that the region containing residues 298-506 of rAxin is sufficient and necessary for it to form a complex with β-catenin. To examine whether β-catenin Table I . Two-hybrid interactions between β-catenin and rAxin Growth on selective media (-His) β-Galactosidase activity pGAD pGAD/β-catenin pGAD pGAD/β-catenin
L40 was co-transformed with pBTM116HA or pBTM116HA/rAxin and pGAD or pGAD/β-catenin. To assay for protein interaction-induced growth, cells were streaked on selective medium (-His) containing 3-aminotriazole and incubated for 5 days at 25°C. To assay for β-galactosidase activity, cells were streaked on permissive medium (ϩHis) and incubated for 3 days at 30°C, then β-galactosidase activity was measured. (-), negative; (ϩ), positive.
directly binds to rAxin and which region of β-catenin is involved in this binding, various deletion mutants of β-catenin were purified from E.coli as GST fusion proteins. GST-β-catenin-(1-423), GST-β-catenin-(132-423) and GST-β-catenin-(175-423), but not GST-β-catenin-(1-131) or GST-β-catenin-(423-781), bound to MBP-rAxin-(298-506) ( Figure 6D ). GST-β-catenin-(132-423) contains seven armadillo repeats, and β-catenin-(175-423) lacks the first armadillo repeat. The N-terminal region containing the first armadillo repeat of β-catenin is known to be involved in its interaction with α-catenin (Hülsken et al., 1994; Funayama et al., 1995) . Therefore, these results demonstrate that rAxin directly interacts with the armadillo repeats 2-7 of β-catenin and that it does not compete with α-catenin for binding to β-catenin. The interaction of rAxin with β-catenin was confirmed by the yeast two-hybrid method (Table I) .
Effect of the phosphorylation of rAxin on its interaction with GSK-3β and β-catenin
From the results of Figures 3-6 , we found that rAxin-(298-506) is phosphorylated by GSK-3β and binds to both GSK-3β and β-catenin. We therefore examined whether the phosphorylation of rAxin affects its interaction with GSK-3β and β-catenin. When MBP-rAxin-(298-506) was incubated with GST-GSK-3β in the presence or absence of ATP, GST-GSK-3β bound to the phosphorylated and non-phosphorylated MBP-rAxin-(298-506) with similar efficiency ( Figure 7A ). GST-β-catenin also bound to the phosphorylated and non-phosphorylated MBP-rAxin-(298-506) without any significant difference ( Figure 7B ). These results indicate that the phosphorylation of rAxin does not affect its affinity for GSK-3β and β-catenin.
Ternary complex formation of GSK-3β, rAxin and β-catenin
The observations that rAxin directly binds to both GSK-3β and β-catenin prompted us to examine whether these three proteins form a ternary complex. When Myc-rAxin and HA-GSK-3β were co-expressed in COS cells and HA-GSK-3β was immunoprecipitated with the anti-HA antibody, both Myc-rAxin and endogenous β-catenin were detected in the HA-GSK-3β immune complex ( Figure 8A , lanes 1 and 4). However, in the absence of Myc-rAxin, β-catenin was not detected in the HA-GSK-3β immune complex ( Figure 8A , lanes 2 and 5). Furthermore, MycrAxin-endogenous GSK-3β complex was co-precipitated with GST-β-catenin, and inversely Myc-rAxin-endogenous β-catenin complex was co-precipitated with GST-GSK-3β ( Figure 8B ). These results suggest that GSK-3β, rAxin and β-catenin form a ternary complex in intact cells and that GSK-3β and β-catenin interact with separate sites on rAxin. To investigate this possibility, two deletion mutants, MBP-rAxin-(353-437) and MBP-rAxin-(437-506), were purified from E.coli. GST-GSK-3β bound to MBP-rAxin-(298-506) and MBP-rAxin-(353-437) but not to MBP-rAxin-(437-506) ( Figure 8C ). On the other hand, GST-β-catenin bound to MBP-rAxin-(298-506) and MBP-rAxin-(437-506) but not to MBP-rAxin-(353-437) ( Figure 8C ). These results clearly indicate that the binding site of rAxin for GSK-3β is distinct from the β-catenin-binding site.
Phosphorylation of β-catenin by GSK-3β in the presence of rAxin
It has been shown that β-catenin has a consensus sequence phosphorylation site for GSK-3β and that β-catenin mutants lacking this site are more stable than wild-type Yost et al., 1996) . Therefore, it is thought that the phosphorylation of β-catenin by GSK-3β regulates the stabilization of β-catenin. However, it has been reported that mammalian GSK-3β does not 
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phosphorylate β-catenin significantly in vitro . Therefore, we examined whether GSK-3β phosphorylates β-catenin in the conditions under which these proteins form a complex with rAxin. In the absence of MBP-rAxin-(298-506), no significant phosphorylation of GST-β-catenin by GST-GSK-3β was observed, whereas in its presence the phosphorylation was greatly increased ( Figure 9A and D) . MBP-rAxin-(298-506) enhanced GST-β-catenin phosphorylation by GST-GSK-3β in a dosedependent manner ( Figure 9B and E) . When the amount of GST-β-catenin was increased, its phosphorylation level was also increased ( Figure 9C and F) . Thus, it appears that rAxin promotes GSK-3β-dependent phosphorylation of β-catenin. Furthermore, GST-β-catenin-(1-423) but not GST-β-catenin-(423-781) was phosphorylated by GST-GSK-3β in the presence of rAxin-(298-506) (data not shown). These results were consistent with the observations that GST-β-catenin-(1-423) interacted with rAxin and that it has a consensus sequence phosphorylation site for GSK-3β. Since MBP-rAxin-(298-506) does not increase the phosphorylation of GSK peptide 1 by GST-GSK-3β (data not shown), it is unlikely that rAxin activates GSK-3β kinase activity. Taken together, these results suggest that rAxin plays a role in placing β-catenin in the vicinity of GSK-3β, thereby enhancing the phosphorylation of β-catenin by GSK-3β.
Discussion
We have isolated a protein which interacts with GSK-3β and have determined its primary structure. Since this protein has been found to be 94% identical with mouse Axin (Zeng et al., 1997) , we have named it rAxin. Axin is the product of the Fused locus (Zeng et al., 1997) . It has been found that the mouse mutant of Fused carries recessive mutations that are lethal at E8-E10, and that a remarkable property of embryos homozygous for this mutant is a duplication of the embryo axis (Perry et al., 1995) . When Axin mRNA is injected into Xenopus embryos, most embryos develop with strong axial defects (Zeng et al., 1997) . Co-expression of Axin inhibits the induction of the secondary dorsal axis by Wnt, Dsh and kinase-negative GSK-3, while it does not affect β-cateninand Siamois-induced secondary axis formation. Although injection of Noggin or dominant-negative bone morphogenetic protein receptor also causes secondary axis formation, Axin fails to block this induction (Zeng et al., 1997) . These results indicate that Axin exerts its function on axis formation by specifically inhibiting the Wnt pathway. However, no biochemical information has been provided on how and with which components of the Wnt pathway it might interact. We have shown that GSK-3β interacts with rAxin in COS cells and that residues 353-437 of rAxin are responsible for the interaction. This association has been observed with wild-type but not with catalytically inactive mutants of GSK-3β, GSK-3β K85M and GSK-3β Y216F . It has been reported that insect cell-expressed GSK-3β Y216F showed 10% activity of the wild-type (Hughes et al., 1993) , but our results have shown that neither HA-GSK-3β Y216F in COS cells nor bacterially expressed GST-GSK-3β Y216F exhibit kinase activities. Although we do not know the reasons why GSK-3β Y216F kinase activities are different among expression systems, our results suggest that GSK-3β without kinase activity does not have the ability to bind to rAxin. It is known that recombinant GSK-3β has a specific activity less than that of mammalian expressed protein (Hughes et al., 1993) . Our in vitro experiments have shown that GST-GSK-3β binds to MBP-rAxin-(298-506). These results suggest that the interaction of GSK-3β with rAxin requires its kinase activity and that even a low specific kinase activity is sufficient for the interaction. Alternatively, the interaction of GSK-3β with rAxin may require the structure of GSK-3β which is catalytically active rather than the kinase activity itself, and K85 and Y216 may be important for keeping the rAxin-interacting domain of GSK-3β in a binding conformation. We have also demonstrated that rAxin is phosphorylated by GST-GSK-3β and that rAxin-(298-506) contains at least one phosphorylation site for GST-GSK-3β. Since we have used immunoprecipitated rAxin as a GST-GSK-3β substrate, we cannot rule out the possibility that rAxin is co-precipitated with other protein kinases and that the protein kinases are activated by GSK-3β and phosphorylate rAxin. However, MBP-rAxin-(298-506) is phosphorylated by GST-GSK-3β, and mutations in the consensus sequence phosphorylation sites for GSK-3 reduce the phosphorylation of MBP-rAxin-(298-506) by GST-GSK-3β. Therefore, it is likely that GSK-3β directly phosphorylates rAxin and that SANDSEQQS 330 , SDADTLSLT 341 and SLTDS 343 are the phosphorylation sites for GSK-3β. These results are consistent with the observations that 3-4 mol of phosphate are incorporated into 1 mol of immunoprecipitated Myc-rAxin. Of course, it remains to be clarified whether protein kinases other than GSK-3β interact with and phosphorylate rAxin. Although prior phosphorylation of a proto-substrate by a distinct protein kinase is required for the phosphorylation by GSK-3, in several substrates, such as glycogen synthase, inhibitor-2, CREB and APC (Plyte et al., 1992; Fiol et al., 1994; Rubinfeld et al., 1996) , the phosphorylation of rAxin by GSK-3β does not require prior phosphorylation.
Our results have shown that rAxin interacts not only with GSK-3β but also with β-catenin, and that residues 437-506 of rAxin are responsible for its binding to β-catenin. The primary structure of β-catenin consists of an N-terminal portion of~130 amino acids, a central region of 550 amino acids that contains 12 repeats of 42 amino acids known as armadillo repeats, and a C-terminal region of 110 amino acids (Huber et al., 1997) . We have demonstrated that rAxin interacts directly with the region containing armadillo repeats 2-7 of β-catenin. The armadillo repeat region of β-catenin has been shown to bind to α-catenin, cadherin, APC and LEF/TCF (Hülsken et al., 1994; Funayama et al., 1995; Behrens et al., 1996; Molenaar et al., 1996; Polakis, 1997) . It remains to be clarified whether rAxin and these proteins share a common binding site on β-catenin. It is unlikely that rAxin does not compete with α-catenin for binding to β-catenin, since the N-terminal region containing the first armadillo repeat of β-catenin is involved in its interaction with α-catenin (Hülsken et al., 1994; Funayama et al., 1995) . It has been reported that neither β-catenin-(1-423) nor β-catenin-(423-781) interact independently with APC (Rubinfeld et al., 1995) . Therefore, the Axin-binding site of β-catenin may be distinct from the binding site for APC. It has been shown that APC forms a complex with β-catenin and that the phosphorylation of APC by GSK-3β increases the binding of APC to β-catenin . However, the phosphorylation of rAxin by GSK-3β does not affect its binding to GSK-3β and β-catenin. Therefore, we do not know the physiological significance of the phosphorylation of rAxin by GSK-3β.
We have demonstrated that rAxin, GSK-3β and β-catenin form a ternary complex in COS cells. Consistent with these observations, GSK-3β and β-catenin bind to separate sites on rAxin, and these sites are adjacent. Furthermore, we have found that rAxin promotes GSK-3β-dependent phosphorylation of β-catenin. Approximately 0.2-0.3 mol of phosphate was incorporated into 1 mol of GST-β-catenin in the presence of MBP-rAxin-(298-506). These results are the first demonstration of the mechanism by which GSK-3β phosphorylates β-catenin efficiently. It is well known that the phosphorylation of β-catenin is essential for its degradation process . Therefore, Axin may cause β-catenin degradation by interacting with both GSK-3β and β-catenin and enhancing the phosphorylation of β-catenin. This model is consistent with the observations that Axin negatively regulates the Wnt signaling pathway in development of Xenopus embryos (Zeng et al., 1997) . Although it is not known whether APC promotes GSK-3β-dependent phosphorylation of β-catenin, APC and Axin may regulate β-catenin degradation by different mechanisms.
rAxin possesses an RGS homologous domain. Recently, a family of RGS proteins has been identified in eukaryotic species ranging from yeast to mammals (Dohlman and Thorner, 1997) . The RGS domain of members of this family binds to the GTP-but not GDP-bound form of G α and stimulates GTP hydrolysis of G α . Although there is no direct evidence showing that G protein is involved in the Wnt signaling pathway, it is intriguing to speculate that the RGS domain of Axin is a functional G α GAP and that Axin thereby inhibits the Wnt signaling pathway. The three-dimensional structure of a stable complex of RGS4 and Gi α has been determined (Tesmer et al., 1997) . Residues that form the hydrophobic core of the RGS box of RGS4 are well conserved in the RGS domain of rAxin. However, 11 residues of RGS4 that make direct contact with Gi1 α are not conserved in the RGS domain of rAxin, with the exception of one amino acid. Indeed, our preliminary experiments demonstrate that the RGS domain of rAxin neither stimulates the GTP hydrolysis of Gi2 α nor binds to the GTP-bound form of Gi2 α (unpublished data). So far, all of the RGS proteins currently characterized bind to members of the Gi α class of G protein α subunits, including Go α , Gz α and Gq α . Therefore, the RGS domain of rAxin may regulate the G protein activity of members other than the Gi α class. Alternatively, it may have an additional activity of transmitting the signal by interacting with other protein(s). It has been shown that ΔRGS, a mutant of Axin in which the RGS domain is deleted, acts as a potent dorsalizer, producing a secondary axis, and that Axin blocks the axis-inducing activity of ΔRGS (Zeng et al., 1997) . These results indicate that ΔRGS acts through a dominant-negative mechanism to inhibit an endogenous Axin activity and that it competes for binding to a protein with which Axin normally interacts. Our observation that the RGS domain is distinct from the GSK-3β-and β-catenin-binding sites of rAxin is consistent with these results. The RGS domain of rAxin could be involved in the degradation of β-catenin. In addition to the RGS domain, rAxin has a domain homologous to the N-terminal region of Dsh. Since the function of this region of Dsh is not known, the role of the Dsh homologous domain in the action of rAxin remains to be clarified.
It has been demonstrated that Axin negatively regulates the Wnt signaling either at the level of GSK-3 or further downstream, and that it acts upstream of β-catenin (Zeng et al., 1997) . Three possible mechanisms of the mode of action of Axin have been suggested: (i) Axin increases the level of the phosphorylation of GSK-3 substrates by inhibiting the protein dephosphorylation; (ii) Axin stimulates GSK-3 activity; or (iii) the RGS domain of Axin acts to inhibit the Wnt signaling pathway, probably by inhibiting the G protein functions. In addition to these possibilities, our observations demonstrated here suggest that the interaction of Axin with GSK-3β and β-catenin promotes GSK-3β-dependent phosphorylation of β-catenin, thereby leading to the degradation of β-catenin. Although our experiments were performed in COS cells that overexpressed rAxin and in vitro, it is possible that the interactions that we observed in COS cells are representative of intact cells physiologically expressing Axin.
Materials and methods
Materials and chemicals
Yeast strain L40, plasmid vectors for two-hybrid screening, a pGAD10-derived rat brain cDNA library, pBSSK/GSK-3β, pBSSK/β-catenin, pGAD/β-catenin, a λZAP rat brain cDNA library, pEF-BOS, pGEX-KG, a peptide substrate of GSK-3 (GSK peptide 1), the anti-HA antibody and the anti-MBP antibody were kindly supplied by Drs Y.Takai and K.Tanaka (Osaka University, Suita, Japan), J.R.Woodgett (Ontario Cancer Institute, Toronto, Canada), A.Nagafuchi and S.Tsukita (Kyoto University, Kyoto, Japan), S.Kuroda and K.Kaibuchi (Nara Institute Science and Technology, Ikoma, Japan), Y.Hata (ERATO, Japan Science and Technology Corp., Kobe, Japan), S.Nagata (Osaka University, Suita, Japan) (Mizushima and Nagata, 1990) , F.Tamanoi (University of California, Los Angeles, CA), C.W.Turck (University of California, San Francisco, CA) (Murai et al., 1996) , Q.Hu (Chiron Corp., CA) and M.Nakata (Sumitomo Electric Industries, Yokohama, Japan), respectively. The anti-Myc antibody was prepared from 9E10 cells. GST-GSK-3β was purified from E.coli as described (Murai et al., 1996) . GST and MBP fusion proteins were purified from E.coli according to the manufacturer's instructions. The anti-GSK-3β and β-catenin antibodies were purchased from Transduction Laboratories (Lexington, KY), and the anti-GSK-3α antibody was from UBI (Lake Placid, NY). [α-32 P]dCTP and [γ-32 P]ATP were obtained from Amersham Inc. (Buckinghamshire, UK). Other materials were from commercial sources.
Plasmid construction
To construct pBTM116HA/GSK-3β, pBSSK/GSK-3β was digested with BclI and EcoRI, and blunted with Klenow fragment. The 1.3 kb fragment was inserted into pBTM116HA which was digested with BamHI and blunted with Klenow fragment. To construct pBSKS/rAxin, the 0.2 kb fragment encoding rAxin-(1-70) with a SmaI site at the 5Ј end was synthesized by PCR. This fragment was digested with SmaI and BglII and inserted into the SmaI-and BglII-cut pBSKS containing the 3.2 kb fragment encoding rAxin prepared from the library in pGAD10. pBSKS/ rAxin was digested with SmaI and EcoRV, and the 3.2 kb fragment encoding rAxin was inserted into pMAL-c2 which was digested with XbaI and blunted with Klenow fragment to construct pMAL-c2/rAxin. To construct pBTM116HA/rAxin, pMAL-c2/rAxin was digested with EcoRI and SalI, and the 3.2 kb fragment encoding rAxin was inserted into the EcoRI-and SalI-cut pBTM116HA. The 1.3 kb fragments encoding GSK-3β K85M and GSK-3β Y216F with XbaI and SmaI sites synthesized by PCR were inserted into the XbaI-and SmaI-cut pCGN to construct pCGN/GSK-3β K85M and pCGN/GSK-3β Y216F . pCGN/GSK-3β and pGEX-2T/GSK-3β were constructed as described (Murai et al., 1996) . To construct pGEX-2T/GSK-3β K85M and pGEX-2T/GSK-3β Y216F , the 1.3 kb fragments encoding GSK-3β K85M and GSK-3β Y216F with EcoRV and EcoRI sites synthesized by PCR were digested with EcoRV and EcoRI and inserted into the SmaI-and EcoRI-cut pGEX-2T. To construct pEF-BOS-Myc, the fragment encoding the Myc epitope synthesized by PCR was inserted into pEF-BOS which was digested with XbaI and blunted with Klenow fragment. To construct pEF-BOSMyc/rAxin, pBSKS/rAxin was digested with SmaI and EcoRV, and the 3.2 kb fragment encoding rAxin was inserted into pEF-BOS-Myc which was digested with XbaI and blunted with Klenow fragment. pBSKS/ rAxin was digested with SacI, and the 1.7 kb fragment encoding rAxin-(298-832) was inserted into the SacI-cut pUC19 to construct pUC19/ rAxin-(298-832). pUC19/rAxin-(298-832) was digested with EcoRI and SmaI and blunted with Klenow fragment, and the 1.7 kb fragment encoding rAxin-(298-832) was inserted into pBJ-Myc which was digested with BamHI and blunted with Klenow fragment to construct pBJMyc/rAxin-(298-832). To construct pBSKS/rAxin-(508-832), pBSKS/ rAxin was digested with PstI and EcoRV and blunted with T4 DNA polymerase. The 1.7 kb fragment encoding rAxin-(508-832) was inserted into the SmaI-cut pBSKS. After SpeI linker was inserted into the EcoRVcut pBSKS/rAxin-(508-832), pBSKS/rAxin-(508-832) was digested with SpeI, and the 1.7 kb fragment encoding rAxin-(508-832) was inserted into the XbaI-cut pEF-BOS-Myc to construct pEF-BOS-Myc/ rAxin-(508-832). To construct pBSKS/rAxin-(713-832), pBSKS/rAxin was digested with PvuII and EcoRV, and the 1.0 kb fragment encoding rAxin-(713-832) was inserted into the SmaI-cut pBSKS. To construct pBJ-Myc/rAxin-(713-832), pBSKS/rAxin-(713-832) was digested with XbaI and EcoRV, and the 1.0 kb fragment was inserted into pBJ-Myc which was digested with BamHI, blunted with Klenow fragment and digested with XbaI. To construct pBJ-Myc/rAxin-(1-229), pBSKS/rAxin was digested with SacI and SmaI and blunted with T4 DNA polymerase. The 0.69 kb fragment was inserted into pBJ-Myc, which was digested with XbaI and blunted with Klenow fragment. To construct pEF-BOSMyc/rAxin-(1-713), the 0.94 kb fragment encoding rAxin-(401-713) with XbaI sites was synthesized by PCR, digested with XbaI and inserted into the XbaI-cut pEF-BOS-Myc/rAxin. To construct pBJ-Myc/rAxin-(298-713), Myc epitope-tagged rAxin-(298-713) with EcoRI sites synthesized by PCR was digested with EcoRI and inserted into EcoRI-cut pBJ-1. To construct pEF-BOS/Myc-rAxin-(298-506), pBJ-Myc/rAxin-(298-832) was digested with EcoRI and PstI, blunted with T4 DNA polymerase, and the 0.68 kb fragment was inserted into pEF-BOS which was digested with XbaI and blunted with Klenow fragment. To construct pMAL-c2/Myc-rAxin-(298-506), pBJ-Myc/rAxin-(298-832) was digested with EcoRI and PstI, and the 0.68 kb fragment was inserted into the EcoRI-and PstI-cut pMAL-c2. To construct pUC19/rAxin-(298-506, 322/326/330A), the 0.62 kb fragment encoding rAxin-(298-506) in which Ser322, Ser326 and Ser330 were substituted by Ala, was synthesized by PCR, digested with SacI and BglII and inserted into the SacI-and BamHI-cut pUC19. To construct pMAL-c2/rAxin-(298-506, 322/326/330A), pUC19/rAxin-(298-506, 322/326/330A) was digested with EcoRI and HindIII, and the fragment was inserted into the EcoRIand HindIII-cut pMAL-c2. To construct pMAL-c2/rAxin-(298-506, 333/337/341A) and pMAL-c2/rAxin-(298-506, 339/343A), the same procedures as the construction of pMAL-c2/rAxin-(298-506, 322/326/ 330A) were performed. To construct pEF-BOS-Myc/rAxin-(353-506), pBSKS/rAxin was digested with BamHI and PstI and blunted with T4 DNA polymerase. The 0.46 kb fragment encoding rAxin-(353-506) was inserted into pEF-BOS-Myc which was digested with XbaI and blunted with Klenow fragment. pEF-BOS-Myc/rAxin-(353-506) was digested with BamHI and NcoI and blunted with Klenow fragment. The 0.25 kb fragment encoding rAxin-(353-437) was inserted into pMAL-c2 which was digested with XbaI and PstI and blunted with T4 DNA polymerase to construct pMAL-c2/rAxin-(353-437). To construct pMAL-c2/rAxin-(437-506), pBJ-Myc/rAxin-(298-713) was digested with NcoI and blunted with Klenow fragment, then digested with PstI. The 0.21 kb fragment encoding rAxin-(437-506) was inserted into pMAL-c2 which was digested with XbaI and blunted with Klenow fragment, then digested with PstI. To construct pGEX-2T/β-catenin, pBSSK/β-catenin was digested with XhoI and blunted with Klenow fragment, and the 2.7 kb fragment was inserted into the SmaI-cut pGEX-2T. To construct pGEX-2T/β-catenin-(1-423), pBSSK/β-catenin was digested with BamHI and EcoRI, and the 1.3 kb fragment encoding β-catenin-(1-423) was inserted into the BamHI-and EcoRI-cut pGEX-2T. To construct pGEX-KG/β-catenin-(423-781), pBSKS/β-catenin was digested with EcoRI and XhoI, and the 1.4 kb fragment encoding β-catenin-(423-781) was inserted into the EcoRI-and XhoI-cut pGEX-KG. To construct pGEX-2T/β-catenin-(1-131), pGEX-2T/β-catenin-(132-423) and pGEX-2T/β-catenin-(175-423), the fragments encoding β-catenin-(1-131), β-catenin-(132-423) and β-catenin-(175-423) with BamHI and EcoRI sites were synthesized by PCR, digested with BamHI and EcoRI, and inserted into the BamHIand EcoRI-cut pGEX-2T.
Yeast two-hybrid screening
Yeast strain L40 (MATa trp1 leu2 his3 ade2 LYS2::lexA-HIS3 URA3::-lexA-lacZ) was used as a host for the two-hybrid screening (Vojtek et al., 1993) . A strain L40 carrying pBTM116HA/GSK-3β was transformed with a rat brain cDNA library constructed in pGAD10. pBTM116HA/ GSK-3β directs the expression of a fusion between the DNA-binding domain of LexA and the entire GSK-3β from an ADH promoter. Approximately 3.7ϫ10 6 transformants were screened for the growth on SD plate media lacking tryptophan, leucine and histidine as evidenced by transactivation of a LexA-HIS3 reporter gene and histidine prototrophy. His ϩ colonies were scored for β-galactosidase activity. Plasmids harboring cDNAs were recovered from positive colonies and the nucleotide sequences of plasmid DNAs which conferred the LacZ ϩ phenotype on L40 containing pBTM116HA/GSK-3β were determined.
Molecular cloning of rAxin
To obtain full-length cDNA of GSK-3β-interacting protein, the clone isolated by the yeast two-hybrid method was labeled with random primers and [α-32 P]dCTP and used to screen a λZAP rat brain cDNA library. A number of positive clones were isolated and all clones, collectively spanning 3.5 kb, were sequenced using double-stranded templates, a Thermo Sequenase pre-mixed cycle sequencing kit (Amersham Inc., Buckinghamshire, UK) and a Hitachi DNA sequencer SQ-5500 (Hitachi Ltd., Tokyo, Japan).
Interaction of GSK-3β, GSK-3α and β-catenin with rAxin in COS cells COS cells (10 cm diameter dish) transfected with pCGN-, pBJ-and pEF-BOS-derived plasmids were lysed as described (Kikuchi and Williams, 1996) . rAxin and its deletion mutants were tagged with Myc epitope at their N-termini. GSK-3β and its mutants were tagged with HA epitope at their N-termini. The lysates (50-800 μg of protein) were immunoprecipitated with the anti-Myc or HA antibody, then the precipitates were probed with the anti-Myc, HA, GSK-3β, GSK-3α and
